Article
Engineering human pluripotent stem cell lines to evade xenogeneic transplantation barriers
11 Jan 2024
Abstract excerpt
Successful allogeneic human pluripotent stem cell (hPSC)-derived therapies must overcome immunological rejection by the recipient. To build reagents to define these barriers, we genetically ablated β2M , TAP1 , CIITA , CD74 , MICA , and MICB to limit expression of HLA-I, HLA-II, and natural killer (NK) cell activating ligands in hPSCs. Transplantation of these cells that also expressed covalent single chain...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
